Real World Effectiveness and Safety of Deutetrabenazine in Adult Chinese Patients With Huntington's Disease (HD) Chorea in China

Real World Effectiveness and Safety of Deutetrabenazine in Chinese Patients With Huntington's Disease (HD) Chorea

The Primary Objective: To evaluate the real-world effectiveness of deutetrabenazine in adult patients with chorea associated with Huntington's disease in China.

The Secondary Objectives: To evaluate the real-world safety of deutetrabenazine in adult patients with chorea associated with Huntington's disease in China.

Inclusion Criteria:

• Participants with clinically confirmed diagnosis of chorea associated with Huntington's Disease (HD)
• Participants whose baseline total maximal chorea (TMC) score ≥ 8
• Participants who are deutetrabenazine-naïve before study entry or who did not receive deutetrabenazine within 30 days of study entry, and who are about to be treated with deutetrabenazine for chorea associated with HD
• Participants who have provided written consent for the use of personal and medical information for study purposes

Exclusion Criteria:

• Participants who have an unstable or serious medical or psychiatric illness at baseline
• Participants with any history of suicidality, untreated or inadequately treated depression
• Participants with certain comorbidities, including hepatic impairment, congenital long QT syndrome, and clinically significant cardiac arrhythmias.
• Participants who received reserpine within 20 days of deutetrabenazine treatment initiation
• Participants who received monoamine oxidase inhibitors within 14 days of deutetrabenazine treatment initiation
• Participants who received vesicular monoamine transporter 2 (VMAT2) inhibitors, e.g., tetrabenazine or valbenazine, within 30 days of deutetrabenazine treatment initiation
• Participants unable to provide a written consent for the study.
• Participants who are participating in another study that includes treatment with an investigational drug and/or intervention at the same time as enrolment in the current study